伊文力莫片，3.1类申报中化药，哪位知道该药相关信息？
Everolimus (RAD-001) (marketed as Certican by Novartis) is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. Much research has also been conducted on Everolimus and other mTOR inhibitors for use in a number of cancers.
Although it does not have FDA approval in the USA, it is approved for use in Europe and Australia, and Phase III trials are being conducted in the US.
Everolimus (RAD-001) (marketed as Certican by Novartis) is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. Much research has also been conducted on Everolimus and other mTOR inhibitors for use in a number of cancers.
Although it does not have FDA approval in the USA, it is approved for use in Europe and Australia, and Phase III trials are being conducted in the US.
适应证 进程
移植排斥 上市
癌症，胰腺癌 III期临床
癌症，肾癌 III期临床
癌症，乳腺癌 II期临床
癌症，非小细胞肺癌 II期临床
骨髓增生异常综合征 II期临床
癌症，慢性淋巴细胞白血病 II期临床
癌症，基质胃肠道癌 II期临床
专利是92年的
就知道这些
Everolimus是依维莫司吧，coco61是不是弄错了？
Everolimus是依维莫司吧，coco61是不是弄错了？
Everolimus (RAD-001) (marketed as Certican by Novartis) is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. Much research has also been conducted on Everolimus and other mTOR inhibitors for use in a number of cancers.
Although it does not have FDA approval in the USA, it is approved for use in Europe and Australia, and Phase III trials are being conducted in the US.
Everolimus (RAD-001) (marketed as Certican by Novartis) is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. Much research has also been conducted on Everolimus and other mTOR inhibitors for use in a number of cancers.
Although it does not have FDA approval in the USA, it is approved for use in Europe and Australia, and Phase III trials are being conducted in the US.
适应证 进程
移植排斥 上市
癌症，胰腺癌 III期临床
癌症，肾癌 III期临床
癌症，乳腺癌 II期临床
癌症，非小细胞肺癌 II期临床
骨髓增生异常综合征 II期临床
癌症，慢性淋巴细胞白血病 II期临床
癌症，基质胃肠道癌 II期临床
专利是92年的
就知道这些
Everolimus是依维莫司吧，coco61是不是弄错了？
Everolimus是依维莫司吧，coco61是不是弄错了？